Synthesis and evaluation of Cy5.5-Rit tracer for specific near-infrared fluorescence imaging of sentinel lymph node
Synthesis and evaluation of Cy5.5-Rit tracer for specific near-infrared fluorescence imaging of sentinel lymph node
复制标题
前哨淋巴结特异性近红外荧光成像Cy5.5-Rit示踪剂的合成与评价
DOI：
10.1016/j.bmcl.2016.07.052
复制
发表时间：
2016
影响因子：
2.7
通讯作者：
Yang Zhi
中科院分区：
文献类型：
--
作者：
Li Nan;Zhu Hua;Li Yan;Wang Jing;Yang Zhi
前哨淋巴结活检（SLNB）是确定原发性乳腺癌转移状态的一项至关重要的技术。在这里，我们报道了一种结合物 Cy5.5-Rituximab (Cy5.5-Rit) 的新用途，它对 CD20 受体具有特异性，作为前哨淋巴结 (SLN) 非侵入性近红外荧光 (NIRF) 成像的成像剂。合成的缀合物 Cy5.5-Rit 的染料与利妥昔单抗的比例接近 1.0。凝胶电泳和质谱分析均证实了 Cy5.5-Rit 的分子完整性。对于体内 NIRF 成像，注射后缀合物在 SLN 中停留长达 9 天。 SLN靶向的体内成像结果也通过体外HE染色得到证实。此外，解剖淋巴结的直接荧光信号表明Cy5.5-Rit与淋巴结细胞表面结合。所有这些结果表明，结合物Cy5.5-Rit具有用于SLN非侵入性光学成像的潜力。
Sentinel lymph nodes biopsy (SLNB) is a critically important technique to determine the metastatic status of primary breast cancer. Here we reported the new use of a conjugate, Cy5.5-Rituximab (Cy5.5-Rit), which is specific toward the CD20 receptor, as an imaging agent for non-invasive near-infrared fluorescence (NIRF) imaging of sentinel lymph nodes (SLN). The conjugate, Cy5.5-Rit, was synthesized with the ratio of dye to Rituximab close to 1.0. Both gel electrophoresis and mass spectrometry analysis confirmed the molecular integrity of Cy5.5-Rit. For in vivo NIRF imaging, the conjugate stayed in SLN as long as 9 days post injection. The in vivo imaging results of SLN targeting were also confirmed by in vitro HE stain. In addition, the direct fluorescence signal of dissected lymph node demonstrated that Cy5.5-Rit binds to the surface of lymph node cells. All of these results showed that the conjugate Cy5.5-Rit has potential for non-invasive optical imaging of SLN.